Adicet Bio, Inc. is a biotech company that develops gamma delta T cell therapies for the treatment of cancer and other diseases. They utilize genetic engineering to improve tumor targeting and immune system response in patients, with one product, ADI-001, in Phase I clinical trials for non-Hodgkin's lymphoma. The company is based in Boston, Massachusetts and is also developing ADI-002 for treatment of solid tumors.